ȸ¿ø±¤Àå Çмú´ëȸ

Çмú´ëȸ

¼ºÀγ²¼ºÀÇ ºñ¸¸µµ,üÁú¾çÁö¼ö,»ç¸Á·ü
µî·ÏÀÏ : 2002.09.27 Á¶È¸¼ö : 2954 ÀÛ¼ºÀÚ : ¹Ú³ëÁØ
Int J Obes Relat Metab Disord 2002 Mar;26 (3):410-6 Related Articles, Books, LinkOut Differential associations of body mass index and adiposity with all-cause mortality among men in the first and second National Health and Nutrition Examination Surveys (NHANES I and NHANES II) follow-up studies. Allison DB, Zhu SK, Plankey M, Faith MS, Heo M. Department of Biostatistics and Clinical Nutrition Research Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. ¸ñÀû: üÁú·®Áö¼ö(BMI)¿Í »ç¸Á·ü°£¿¡ ÀÚÁÖ °üÂûµÇ´Â U ÀÚÇü °ü°è´Â, BMI¿¡¼­ Áö¹æ·®(fat mass)°ú Á¦Áö¹æ·® (fat-free mass)¿ä¼ÒÀÇ »ó¹ÝµÈ È¿°ú·Î ÀÎÇØ »ç¸Á·ü¿¡ ¿µÇâÀ» ÁÖ´Â °ÍÀÏÁöµµ ¸ð¸¥´Ù´Â °¡¼³À» °ËÁõÇϱâ À§ÇÔ µðÀÚÀÎ: ÀüÇâÀûÄÚȣƮ¿¬±¸·Î½á NHANES(National Health and Nutrition Examination Surveys) I°ú NHANES IIÀÇ »ç¸ÁÀ» ÃßÀû. ´ë»ó: NHANES I °ú II¿¡ Âü°¡Çß´ø 25-75¼¼ »çÀÌÀÇ ³² ÀÚ Áß ÃÑ 10169¸íÀÌ ºÐ¼®¿¡ ¼±ÅõǾú °í ÃßÀûÀº 1992³â±îÁö °è¼ÓµÇ¾ú´Ù. Æò±Õ ÃßÀû±â°£Àº NHANES I´Â 14.6³â, NHANES II´Â 12.9³âÀ̾ú´Ù. Âü°¡ÀÚÀÇ 98%°¡ ¼º°øÀûÀ¸·Î ÃßÀûµÇ¾ú °í ¿¬±¸±â°£ µ¿¾È ÃÑ 3722¸íÀÇ »ç¸ÁÇÏ¿´ ´Ù. ÃøÁ¤: Áö¹æ·® ôµµ·Î´Â °ß°©ÇÏ ¹× »ïµÎ¹Ú±Ù ÇǺÎÁÖ¸§ µÎ²²°¡, Á¦Áö¹æ·® ôµµ·Î´Â »ó¿ÏµÑ·¹°¡ ¾²¿´´Ù. ³ªÀÌ, Èí¿¬»óÅÂ, ÀÎÁ¾, ±³À°¼öÁØÀ» º¸Á¤Çϰí Cox proportional hazards modelÀ» ÀÌ ¿ë, BMI, Áö¹æ·®, Á¦Áö¹æ·®°ú ¸ðµç »ç¸Á¿øÀΰúÀÇ ¿¬°ü ¼ºÀ» °ËÁ¤ÇÏ¿´´Ù °á°ú: BMI¿Í »ç¸Á·üÀº ¾à27kg/m2À» °æ°è·Î UÀÚÇüÀÇ »ó °ü°ü°è¸¦ º¸¿´À¸³ª ±× ¸ðµ¨¿¡ üÁö ¹æ·®°ú Á¦Áö¹æ·®ÀÇ ÁöÇ¥¸¦ Ãß°¡Çϸé BMI¿Í »ç¸Á·ü°£ ÀÇ °ü°è´Â °ÅÀÇ Á÷¼±¿¡ °¡±õ°Ô ºñ·ÊÇÏ ¿© Áõ°¡ÇÏ¿´´Ù. ´õ¿íÀÌ Ã¼Áö¹æÁöÇ¥¿Í »ç¸Á·ü°ú´Â Á÷¼± ÀûÀ¸·Î ºñ·ÊÇÏ¿© Áõ°¡Çϰí Á¦Áö¹æÁöÇ¥ ¿Í »ç¸Á·ü°úÀÇ °ü°è´Â Á÷¼±ÀûÀ¸·Î ºñ·ÊÇÏ¿© °¨¼ÒÇÏ¿´ ´Ù. °á·Ð: ÀÌ ¿¬±¸ °á°ú´Â ³Ê¹« ¸¶¸¥ ü°ÝÀÏ °æ¿ì ³ªÅ¸³ª ´Â °Ç°­À§ÇØ ¿µÇâÀÌ ³·Àº Á¦Áö¹æ ¶§¹® À̶ó´Â °¡¼³À» µÞ¹ÞħÇϰí, Á¦Áö¹æ·®ÀÌ ¸¹Áö¸¸ ¸¶¸¥ ü°ÝÀº(marked leanness - as opposed to thinness) ¿ÀÈ÷·Á À̷οî È¿°ú¸¦ º¸¿´´Ù
¹øÈ£Á¦¸ñÀÛ¼ºÀÚµî·ÏÀÏÁ¶È¸
171

Drug therapy of obesity - NEJM

¹Ú³ëÁØ 02.10.10 3321
170

ÃÖ±Ù ºñ¸¸¿¬±¸ÀÇ Áøº¸

¹Ú³ëÁØ 02.10.10 4282
169

ŰÅä»êÀÇ Áö¹æÈí¼ö ¾ïÁ¦ ¿©ºÎ

¹Ú³ëÁØ 02.09.27 3129
168

ÀúÁö¹æ, °í´çÁú½Ä»ç°¡ üÁß°ú Ç÷û ÁöÁú¿¡ ¹ÌÄ¡´Â...

¹Ú³ëÁØ 02.09.27 2758
167

ÇÁ·ÎÁ¦½ºÅ×·Ð ÇÇÀÓ¾àÀÇ Ã¼Áß¿¡´ëÇÑ ¿µÇâ

¹Ú³ëÁØ 02.09.27 2852
166

¾ÆÄ§½Ä»çÀÇ Á߿伺

¹Ú³ëÁØ 02.09.27 3872
165

½ÃºÎÆ®¶ó¹Î(¸®´öÆ¿)À¸·Î ÀÎÇÏ Ã¼Áß °¨·®

¹Ú³ëÁØ 02.09.27 3158

¼ºÀγ²¼ºÀÇ ºñ¸¸µµ,üÁú¾çÁö¼ö,»ç¸Á·ü

¹Ú³ëÁØ 02.09.27 2955
163

¿©¼º È£¸£¸ó¿ä¹ý°ú ºñ¸¸

¹Ú³ëÁØ 02.09.27 3594
162

ºñ¸¸ÇÑ ¿©¼º°ú Á¤»ó¿©¼º¿¡¼­ ¿¡Çdz×ÇÁ¸° ÁÖ»ç

¹Ú³ëÁØ 02.09.27 3048
161

¼ºÀκñ¸¸ÀÇ ¿¹ÃøÀÎÀÚ

¹Ú³ëÁØ 02.09.27 2877
160

ºñ¸¸¿¡¼­ ½ÄÀÌ¿ä¹ýÀ¸·Î üÁß°¨·® ÈÄ

¹Ú³ëÁØ 02.09.27 2818
159

Orlistat(Á¦´ÏÄ®)ÀÇ ºÎÀÛ¿ë °¨¼Ò¹ý

¹Ú³ëÁØ 02.09.27 3466
158

·¾Æ¾ ³óµµ¿Í ÀÎÁ¾ ¹× ÀÎü°èÃø°úÀÇ °ü·Ã¼º

¹Ú³ëÁØ 02.09.27 2970
157

ÀϺ» ºñ¸¸¾ÆÀÇ 12³â°£ Ä¡·áÈÄÀÇ ÃßÀû

¹Ú³ëÁØ 02.09.27 3070
156

¼·½Ä Çൿ°ú üÁßÁõ°¡ ¹× ºñ¸¸°úÀÇ °ü°è

¹Ú³ëÁØ 02.09.27 2751
155

È£¸£¸ó ´ëü ¿ä¹ýÀÇ Áö¹æºÐÆ÷

¹Ú³ëÁØ 02.09.27 2902
154

Ephedrine/caffeine for weight loss

¹Ú³ëÁØ 02.09.27 2748
153

º¸Åø¸®´®ÁÖ»çÁ¦ ÁÖ¸§»ìÁ¦°Å »ç¿ëÁÖÀÇ

¹Ú³ëÁØ 02.09.26 2763
152

"º¸Åø¸®´½ ÁÖ»ç, ÁÖ¸§»ìÄ¡·áÁ¦·Î Çã°¡¹ÞÁö ...

¹Ú³ëÁØ 02.09.25 2685
151

ºñ¸¸ÇÐȸ 10Áֳ⠱â³ä ½ÉÆ÷Áö¾ö °³ÃÖ

¹Ú³ëÁØ 02.09.23 2787
150

·Î½´, ºñ¸¸Ä¡·áÁ¦ Á¦´ÏÄ® OTC Àüȯ ¸ð»ö

¹Ú³ëÁØ 02.09.19 2787
149

À̹øÁÖ¸»¿¡ ´ëÇѺñ¸¸ÇÐȸÀÇÃß°èÇмú´ëȸ¿Í ¿¬¼ö°­...

¹Ú³ëÁØ 02.09.10 4075
148

"Á¦´ÏÄ®Àº ´ç´¢ ¿¹¹æ¿¡µµ È¿°ú"

¹Ú³ëÁØ 02.09.06 2852
147

(º¸Å彺) Varying concentration

¹Ú³ëÁØ 02.09.04 2868
146

(º¸Å彺)treatment of focal hyperhydrosis of t...

¹Ú³ëÁØ 02.09.04 2834
145

(º¸Å彺) treatment of the lower eyelid

¹Ú³ëÁØ 02.09.04 2712
144

(º¸Å彺) treatment of mid / lower face & neck

¹Ú³ëÁØ 02.09.04 2615
143

(º¸Å彺) therapy of mimic facial lines

¹Ú³ëÁØ 02.09.04 2719
142

¿îµ¿Ã³¹æÀÇ Çö½Ç1 (¼ÛÁ¾ÀÏ)

¹Ú³ëÁØ 02.09.02 3543
  60 61 62 63 64 65 66